Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 20 September 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the "Company")
Board
change
GSK
appoints new CEO
GSK
today announces that Emma Walmsley, currently Chief Executive
Officer (CEO) of GSK's Consumer Healthcare division, is appointed
GSK CEO Designate and will succeed Andrew Witty as GSK CEO, when he
retires on 31March 2017. Emma will join the GSK Board of Directors
from 1 January 2017
Emma is
currently CEO of GSK Consumer Healthcare, one of the world's
largest consumer health companies, established in 2015 following
completion of GSK's three-part transaction with
Novartis.
Prior
to this, Emma was President of GSK Consumer Healthcare and has been
a member of GSK's Corporate Executive Team since 2011. Emma
joined GSK in 2010 from L'Oreal where, over the course of her
17-year career, she held a variety of marketing and general
management roles in the UK, Europe and USA. From 2007 she was based
in Shanghai as General Manager, Consumer Products for L'Oreal
China.
Philip Hampton, GSK Chairman, said: "I
am very pleased to announce Emma's appointment, after what has been
a very thorough and rigorous global selection process carried out
by the GSK Board of Directors.
Emma is
an outstanding leader with highly valuable experience of building
and running major global businesses and a strong track record of
delivering growth and driving performance in healthcare. Under
Andrew's leadership, GSK has successfully developed into a company
with market-leading positions in pharmaceuticals, vaccines and
consumer healthcare. These provide excellent platforms for
sustainable, long-term growth, and we are confident Emma will
successfully build on these strengths."
Emma Walmsley said: "I am
delighted and honoured to be appointed GSK's next CEO. GSK is a
company that leads both in science and in the way it does business.
We have momentum in the Group and as the demand for medical
innovation and trusted healthcare products continues to rise, we
have the opportunity and the potential to create meaningful
benefits for patients, consumers and our shareholders. I'm looking
forward to working with Andrew and other leaders over the next few
months to ensure a smooth handover and to develop plans for 2017
and beyond."
V A Whyte
Company Secretary
20
September 2016
Notes
1.
Remuneration arrangements
GSK's
remuneration policy is currently under review and the Remuneration
Committee will begin consultations with shareholders in the fourth
quarter of 2016. The Committee has decided that the different
elements of Ms Walmsley's remuneration will be determined following
these consultations and will be in line with the new
policy.
The
Committee therefore expects to set and publish a new base salary
for Ms Walmsley on her appointment to the Board on 1 January 2017.
Details of Ms Walmsley's total remuneration, including long-term
incentives, will be published in the Company's 2016 Annual Report.
The remuneration policy will be presented to shareholders for
approval at the Annual General Meeting in 2017.
2.
Shareholding information
Ms
Walmsley has an interest in excess of 200,000 GSK ordinary
shares.
3. Regulatory
disclosure
The
Company confirms that, in respect of Listing Rule 9.6.13R(1), Ms
Walmsley is a Non-Executive Director of Diageo plc, and that, in
respect of Listing Rules 9.6.13R (2)-(6), there are no details to
disclose.
With
effect from 1 January 2017, the composition of the Board of GSK
will be as follows:
|
Sir Philip Hampton
Sir
Andrew Witty
Ms
Emma Walmsley
Mr Simon Dingemans
Dr Moncef Slaoui
Professor Sir Roy Anderson
Mr Vindi Banga
Ms Stacey Cartwright
Dr Vivienne Cox
Ms
Lynn Elsenhans
Dr Jesse Goodman
Ms Judy Lewent
|
Non-Executive Chairman
Chief Executive Officer
Chief Executive Officer Designate
Chief Financial Officer
Chairman, Global Vaccines
Independent Non-Executive Director
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent
Non-Executive Director
Independent Non-Executive Director
|
GSK - one of the world's leading research-based
pharmaceutical and healthcare companies - is committed to improving
the quality of human life by enabling people to do more, feel
better and live longer. For further information please
visit www.gsk.com.
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
David
Mawdsley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Anna
Carruth
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Sarah
Alspach
|
+1 202
715 1048
|
(Washington,
DC)
|
|
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Ziba
Shamsi
|
+44 (0)
20 8047 5543
|
(London)
|
|
|
Tom
Curry
|
+ 1 215
751 5419
|
(Philadelphia)
|
|
|
Gary
Davies
|
+44 (0)
20 8047 5503
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Inside
information
The
information contained in this announcement is inside information.
If you have any queries on this, then please contact Victoria Whyte
GSK Company Secretary (responsible for arranging the release of
this announcement) at GSK House Brentford, Middlesex, TW8 9GS on
+44 208 047 5000.
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any
forward-looking statements or projections made by GSK, including
those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Such factors include, but are not limited to,
those described under Item 3.D 'Risk factors' in the company's
Annual Report on Form 20-F for 2015.
|
|
Registered in England & Wales:
No.
3888792
|
|
|
|
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: September
20, 2016
By: VICTORIA
WHYTE
----------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc